MAOB and Parkinson disease: MAO-B inhibitor rasagiline significantly improved bladder dysfunction in patients with mild PD by increasing bladder capacity, improving first desire to void and reducing residual urine volume, most likely due to an increase in dopamine concentration in the synapses at the central level [69].